Evidence map›Paper›PMID 42216082›Full record

ArticleOrphanet journal of rare diseases2026

Development of a face-validated conceptual model structure for economic evaluation in phenylketonuria, through expert elicitation.

Ania C Muntau, Rongrong Zhang, Anupam Chakrapani, Takashi Hamazaki, Melissa Lah, Danielle J Ruebel, Suresh Vijay, Roberto T Zori, Francois Feillet, Nicola Longo and 5 more

Abstract read
In one paragraph

Article in Orphanet journal of rare diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Ania C MuntauUniversity Children's Hospital, University Medical Center Hamburg-Eppendorf and German Center of Child and Adolescent Health (DZKJ), Hamburg, Germany.
Rongrong ZhangPTC Therapeutics Sweden AB, Askim, Sweden.
Anupam ChakrapaniGreat Ormond Street Hospital for Children, London, UK.
Takashi HamazakiDepartment of Pediatrics, Osaka Metropolitan University Graduate School of Medicine, Osaka, 545-8585, Japan.
Melissa LahIndiana University School of Medicine, Indianapolis, IN, USA.
Danielle J RuebelIndiana University School of Medicine, Indianapolis, IN, USA.
Suresh VijayBirmingham Children's Hospital, Birmingham, UK.
Roberto T ZoriPediatric Genetics and Metabolism, University of Florida, Gainesville, FL, USA.
Francois FeilletReference Centre for Inborn Errors of Metabolism, Department of Pediatrics, Children's Hospital of Nancy, Nancy, France.
Nicola LongoDepartment of Human Genetics, University of California Los Angeles, Los Angeles, CA, USA.
Hope NorthrupDivision of Medical Genetics, The University of Texas Health Science Center at Houston, Houston, TX, USA.
Suzanne HollanderDivision of Genetics and Genomics, Boston Children's Hospital, Boston, MA, USA.
Thomas O'ConnellMedicus Economics, Boston, MA, USA.
Jonathan J WoolleyMedicus Economics, Boston, MA, USA.
Ioannis TomazosPTC Therapeutics Inc, 500 Warren Corporate Center Drive, Warren, N.J, 07059, USA. ytomazos@ptcbio.com.ORCID http://orcid.org/0000-0003-0290-4583

Funding

PTC Therapeutics n/a
6 · The paper itself

Abstract

backgroundClinical complexity and limitations of available evidence make cost-effectiveness analyses (CEAs) in phenylketonuria (PKU) challenging, with no consensus model structure emerging from historical CEAs. This research aimed to elicit perspectives from PKU medical experts regarding approaches for CEA modeling, to inform development of a face-validated model structure.

methodsIn a modified e-Delphi study, clinical experts rated their agreement/disagreement with 14 statements on clinical outcomes, diet, target population, blood phenylalanine (Phe)-level classification, and treatment discontinuation. Separately, a survey of a broader sample of experts elicited perspectives on the prevalence of PKU comorbidities, and biological plausibility of the association of surrogate outcomes with comorbidity risk. Insights informed development of the conceptual structure and parameters for a CEA model.

resultsIn the modified e-Delphi study, participants (N = 11) achieved consensus (≥ 70% agreement/disagreement) on statements on the associations of blood Phe levels with outcomes, unmet need, mechanisms for the association of PKU with chronic comorbidities, and medical management approaches. In the survey (N = 30), ≥ 70% of participants agreed that prevalence of comorbidities is higher in PKU vs. the general population, and that increased natural-protein consumption may reduce comorbidity risk, including for depression, osteoporosis, overweight, anemia, and type two diabetes mellitus. Findings informed development of a CEA model structure comprising five blood Phe level-defined health states (range: ≤120 µmol/L to > 1200 µmol/L), associated with four classes of patient-relevant clinical outcomes in PKU: contemporaneous symptoms/manifestations, intellectual disability, comorbidities, and diet liberalization.

conclusionsIn this research, perspectives were elicited from medical experts in PKU to develop a clinically informed, face-validated conceptual model structure for CEA, and to identify associated parameters. The resulting de novo economic model allows for valuation of numerous important patient-relevant outcomes, enabling modeling of the heterogeneous drivers of unmet need in PKU. The structured expert-elicitation approach used in this research, and documentation of the influence of perspectives elicited on model structure and parameters, support the validity of the model for application in economic evaluation of interventions for PKU.

Indexed as

PhenylketonuriasCost-Benefit AnalysisCost-Effectiveness AnalysisDelphi TechniqueHumansPhenylalaninePhenylalanine

Identifiers

PMID42216082
PMCPMC13435650

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.